Utility of p53 Immunohistochemical Staining for Risk Stratification of Mantle Cell Lymphoma.

IF 1.3 Q4 HEMATOLOGY
Journal of hematology Pub Date : 2024-10-01 Epub Date: 2024-10-11 DOI:10.14740/jh1333
Ibrahim Elsharawi, Sorin Selegean, Michael Carter
{"title":"Utility of p53 Immunohistochemical Staining for Risk Stratification of Mantle Cell Lymphoma.","authors":"Ibrahim Elsharawi, Sorin Selegean, Michael Carter","doi":"10.14740/jh1333","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Inactivating <i>TP53</i> mutations in mantle cell lymphoma (MCL) are associated with poor prognosis. While next-generation sequencing (NGS) is the gold standard for assessing <i>TP53</i>, p53 immunohistochemistry (IHC) is an orthogonal means of evaluating <i>TP53</i> status that has not been well characterized in MCL. In this single tertiary care center laboratory study, we aimed to evaluate the concordance of p53 IHC with the <i>TP53</i> status in cases of MCL in hopes of evaluating if the former could act as an accurate, timely and cost-effective way of risk stratifying these patients.</p><p><strong>Methods: </strong>A total of 47 cases of MCL that had <i>TP53</i> NGS performed were included in this study. The main objective was to correlate NGS findings with p53 IHC results. Secondary objectives included assessment of possible associations between <i>TP53</i> status and other variables (demographics, unique histopathological and IHC features). The turn-around time and cost for NGS and p53 IHC were also compared.</p><p><strong>Results: </strong>Thirteen out of 47 (28%) cases were <i>TP53</i>-mutated by NGS. p53 IHC showed good concordance with NGS, with moderate to high sensitivity (11/13, 85%) and excellent specificity (34/34, 100%). Secondary objectives revealed increased SOX11-negative status in <i>TP53</i>-mutated cases (3/13, 23% vs. 1/29, 3%, P = 0.045). The cost and turn-around time of NGS were approximately of 30- and sixfold those of p53 IHC, respectively.</p><p><strong>Conclusion: </strong>p53 IHC shows good concordance with NGS in MCL, with high specificity and moderate sensitivity for identifying inactivating <i>TP53</i> mutations. Based on our findings, p53 IHC may be an efficient and cost-effective tool in risk stratification of MCL.</p>","PeriodicalId":15964,"journal":{"name":"Journal of hematology","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526585/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/jh1333","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/11 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Inactivating TP53 mutations in mantle cell lymphoma (MCL) are associated with poor prognosis. While next-generation sequencing (NGS) is the gold standard for assessing TP53, p53 immunohistochemistry (IHC) is an orthogonal means of evaluating TP53 status that has not been well characterized in MCL. In this single tertiary care center laboratory study, we aimed to evaluate the concordance of p53 IHC with the TP53 status in cases of MCL in hopes of evaluating if the former could act as an accurate, timely and cost-effective way of risk stratifying these patients.

Methods: A total of 47 cases of MCL that had TP53 NGS performed were included in this study. The main objective was to correlate NGS findings with p53 IHC results. Secondary objectives included assessment of possible associations between TP53 status and other variables (demographics, unique histopathological and IHC features). The turn-around time and cost for NGS and p53 IHC were also compared.

Results: Thirteen out of 47 (28%) cases were TP53-mutated by NGS. p53 IHC showed good concordance with NGS, with moderate to high sensitivity (11/13, 85%) and excellent specificity (34/34, 100%). Secondary objectives revealed increased SOX11-negative status in TP53-mutated cases (3/13, 23% vs. 1/29, 3%, P = 0.045). The cost and turn-around time of NGS were approximately of 30- and sixfold those of p53 IHC, respectively.

Conclusion: p53 IHC shows good concordance with NGS in MCL, with high specificity and moderate sensitivity for identifying inactivating TP53 mutations. Based on our findings, p53 IHC may be an efficient and cost-effective tool in risk stratification of MCL.

p53免疫组化染色在套细胞淋巴瘤风险分层中的实用性
背景:套细胞淋巴瘤(MCL)中的失活TP53突变与预后不良有关。虽然下一代测序(NGS)是评估 TP53 的金标准,但 p53 免疫组化(IHC)是评估 TP53 状态的一种正交手段,在 MCL 中尚未得到很好的表征。在这项单一三级护理中心实验室研究中,我们旨在评估 MCL 病例中 p53 IHC 与 TP53 状态的一致性,希望借此评估前者能否作为一种准确、及时且经济有效的方法对这些患者进行风险分层:本研究共纳入了 47 例进行了 TP53 NGS 检测的 MCL 患者。主要目的是将 NGS 结果与 p53 IHC 结果相关联。次要目标包括评估 TP53 状态与其他变量(人口统计学、独特的组织病理学和 IHC 特征)之间可能存在的关联。此外,还比较了 NGS 和 p53 IHC 的周转时间和成本:47 例病例中有 13 例(28%)经 NGS 鉴定为 TP53 突变。p53 IHC 与 NGS 显示出良好的一致性,具有中到高的灵敏度(11/13,85%)和极好的特异性(34/34,100%)。次要目标显示,TP53 突变病例的 SOX11 阴性率增加(3/13,23% vs. 1/29,3%,P = 0.045)。结论:p53 IHC 与 NGS 在 MCL 中显示出良好的一致性,在鉴定失活 TP53 突变方面具有高特异性和中等灵敏度。根据我们的研究结果,p53 IHC 可能是对 MCL 进行风险分层的一种高效、经济的工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of hematology
Journal of hematology HEMATOLOGY-
自引率
0.00%
发文量
29
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信